CDx DEVELOPMENT SERVICES





CDx DEVELOPMENT SERVICES

Scale access to therapies faster with our broad CDx capabilities



Flexible CDx Development

- Develop fit-for-purpose assays guided by global IVD expertise
- Accelerate timelines with modular development and streamlined data continuity from translational to clinical stages



Global Clinical & Regulatory Support

Accelerate CDx development with CAP/CLIA-certified labs

abcam

- > Seamless integration into CDx development process when clinical trial needs evolve
 - Navigate global submissions with regional regulatory specialists



Fast Commercial Scale-Up

- Reach patients faster with a leading global installed base of IHC instruments and digital scanners
- Drive adoption with support from 1,300+ commercial experts
 - Ensure global access through direct and indirect sales to 100+ countries

LAUNCH




AI-Enabled Portfolio for Precision Dx

- Access 11,000+ antibodies and multimodal CDx via Danaher's Abcam, Beckman Coulter, and Cepheid
 - Integrate Al-power precision diagnostics and Indica Labs' image management system
 - Enable complex biomarker strategies with multiplex IHC solutions











LeicaBiosystems.com



Comprehensive and Seamless Capabilities

Al-Enabled Portfolio for Precision Dx

- Computational Pathology for Next-Gen CDx: Harness Alpowered precision diagnostics through the largest digital pathology scanner installed base
- ➤ Your Single-Source Digital Pathology Partner: End-to-end portfolio including scanners, image management, and Al-powered analysis across the full ecosystem
- ➤ Flexibility to Choose Al Applications: Deploy partner apps or integrate custom solutions to accelerate assay development and optimize patient selection
- ➤ Seamless Tech Transfer: BOND platforms share hardware and reagents to streamline translation from research to clinical

Fast Commercial Scale-Up

- ➤ Installed Base at Scale: 8,000+ IHC instruments and the most (3,000+) digital pathology scanners deployed across 109 countries
- ➤ Clinical Lab Integration: Easily deploy into existing lab workflows to accelerate CDx adoption
- ▶ Day 1 Readiness: Establish CDx from day one by preparing key labs for launch

Y

Flexible CDx Development

- ➤ Assay Expertise Since 1987: Decades of experience optimizing assay sensitivity and specificity
- ➤ Flexible Design Options: Assays developed across detection technologies and plex levels
 - ➤ Tailored Timelines: Modular programs to meet your CDx milestones

✓ G

Global Clinical & Regulatory Support

- > Streamlined Assay Transition: Seamlessly move from RUO to IUO without external hand-offs
- **Deliver** Local Oversight, Global Reach: Experienced clinical and regulatory teams across China, Japan, E.U., and U.S.
- ▶ Proven Regulatory Expertise: 1,300+ IVDs supported globally and expertise in pre-subs, trial submissions, 510(k), IVDR, and global CDx submissions

Partner with Leica Biosystems to accelerate your CDx program



Email: PharmaPartnerships@LeicaBiosystems.com



Copyright © 2025 Leica Biosystems, a division of Leica Microsystems Inc. All Rights Reserved. LEICA and the Leica logo are registered trademarks of Leica Microsystems IR GmbH. Other logos, product and/or company names might be trademarks of their respective owners.

Leica Biosystems is a global leader in workflow solutions and automation. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 9 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Visit LeicaBiosystems.com for more information.